Imunon Q2 net loss narrows to $2.7M, cash $4.7M; first patient dosed in Phase 3 ovarian cancer trial

Imunon, Inc.

2025-Q2 EPS reported -$6.08 vs consensus -$4.20 ▼ miss (-44.6%)

Net loss $2.7M ($2.15/shr) vs $4.8M ($7.64/shr) YoY; operating expenses down 45% to $2.8M.
Cash $4.7M at June 30; received $3.1M in July from warrant exercises and ATM; sufficient into Q4 2025.
First patient dosed July 30 in Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer; 3 sites open, goal 20 by year-end.
Declared 15% stock dividend (0.15 shares/share) payable Aug 21, 2025 to holders of record Aug 7.
Completed 15:1 reverse stock split effective July 25; Nasdaq listing extension granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.